MicroRNA in melanoma

Ochsner Journal

Volumn 10, Issue 2, 2010, Pages 83-92

  Howell Jr , Paul M ^a   Li, Xiaobo ^a   Riker, Adam I ^b   Xi, Yaguang ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b Ochsner Cancer Institute   (United States)

Author keywords

Epigenetics; Melanoma; Metastasis; MicroRNA

Indexed keywords

GENISTEIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MICRORNA; MICRORNA 26A; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RNA; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; HUMAN; LIVER CANCER; MALIGNANT TRANSFORMATION; MELANOCYTE; MELANOMA; NONHUMAN; PROGNOSIS; RADIATION EXPOSURE; RISK FACTOR; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 77954877584     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009 [published online ahead of print May 27, 2009]. CA Cancer J Clin. 2009;59(4):225-249.
2. Knecht AK, Bronner-Fraser M. Induction of the neural crest: a multigene process. Nat Rev Genet. 2002;3(6):453-461.
3. Gupta PB, Kuperwasser C, Brunet JP, et al. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation [published online ahead of print September 4, 2005]. Nat Genet. 2005;37(10):1047-1054.
4. Kasemeier-Kulesa JC, Teddy JM, Postovit LM, et al. Reprogramming multipotent tumor cells with the embryonic neural crest microenvironment. Dev Dyn. 2008;237(10):2657-2666.
5. Rigel DS. Cutaneous ultraviolet exposure and its relationship to the development of skin cancer. J Am Acad Dermatol. 2008;58(5 suppl 2):S129-S132.
6. Bulliard JL, Cox B, Semenciw R. Trends by anatomic site in the incidence of cutaneous malignant melanoma in Canada, 1969-93. Cancer Causes Contro. 1999;10(5):407-416.
7. Rigel DS. The effect of sunscreen on melanoma risk. Dermatol Clin. 2002;20(4):601-606.
8. Haass NK, Smalley KS, Li L, Herlyn M. Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res. 2005;18(3):150-159.
9. Mitra D, Fisher DE. Transcriptional regulation in melanoma. Hematol Oncol Clin North Am. 2009;23(3):447-465.
10. Bedogni B, Warneke JA, Nickoloff BJ, Giaccia AJ, Powell MB. Notch1 is an effector of Akt and hypoxia in melanoma development [published online ahead of print October 16, 2008]. J Clin Invest. 2008;118(11):3660-3670.
11. Hoek K, Rimm DL, Williams KR, et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res. 2004;64(15):5270-5282.
12. Pinnix CC, Lee JT, Liu ZJ, et al. Active Notch1 confers a transformed phenotype to primary human melanocytes [published online ahead of print June 23, 2009]. Cancer Res. 2009;69(13): 5312-5320.
13. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004; 429(6990):457-463.
14. Howell PM Jr, Liu S, Ren S, Behlen C, Fodstad O, Riker AI. Epigenetics in human melanoma. Cancer Control. 2009;16(3):200-218.
15. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs [published online ahead of print October 27, 2008]. Genome Res. 2009;19(1): 92-105.
16. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15-20.
17. Bentwich I, Avniel A, Karov Y, et al. Identification of hundreds of conserved and nonconserved human microRNAs [published online ahead of print June 19, 2005]. Nat Genet. 2005;37(7): 766-770.
18. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science. 2001;294(5543):858-862.
19. Okamura K, Phillips MD, Tyler DM, Duan H, Chou YT, Lai EC. The regulatory activity of microRNA* species has substantial influence on microRNA and 39 UTR evolution [published online ahead of print March 30, 2008]. Nat Struct Mol Biol. 2008;15(4):354-363.
20. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-297.
21. Ambros V. The functions of animal microRNAs. Nature. 2004; 431(7006):350-355.
22. Lee YS, Kim HK, Chung S, Kim KS, Dutta A. Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation [published online ahead of print February 18, 2005]. J Biol Chem. 2005;280(17):16635-16641.
23. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004;64(11): 3753-3756.
24. Carmell MA, Xuan Z, Zhang MQ, Hannon GJ. The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis. Genes Dev. 2002;16(21): 2733-2742.
25. Karube Y, Tanaka H, Osada H, et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 2005;96(2):111-115.
26. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia [published online ahead of print November 14, 2002]. Proc Natl Acad Sci U S A. 2002;99(24): 15524-15529.
27. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers [published online ahead of print February 18, 2004]. Proc Natl Acad Sci U S A. 2004;101(9):2999-3004.
28. Zhang L, Huang J, Yang N, et al. MicroRNAs exhibit high frequency genomic alterations in human cancer [published online ahead of print June 5, 2006]. Proc Natl Acad Sci U S A. 2006;103(24): 9136-9141.
29. Gaur A, Jewell DA, Liang Y, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 2007;67(6):2456-2468.
30. Bemis LT, Chen R, Amato CM, et al. MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res. 2008;68(5):1362-1368.
31. Felicetti F, Errico MC, Segnalini P, Mattia G, Carè A. MicroRNA-221 and -222 pathway controls melanoma progression. Expert Rev Anticancer Ther. 2008;8(11):1759-1765.
32. Worley LA, Long MD, Onken MD, Harbour JW. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Res. 2008;18(3): 184-190.
33. Yan D, Zhou X, Chen X, et al. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met [published online ahead of print November 21, 2008]. Invest Ophthalmol Vis Sci. 2009;50(4):1559-1565.
34. Migliore C, Petrelli A, Ghiso E, et al. MicroRNAs impair MET-mediated invasive growth. Cancer Res. 2008;68(24):10128-10136.
35. Segura MF, Hanniford D, Menendez S, et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor [published online ahead of print February 2, 2009]. Proc Natl Acad Sci U S A. 2009;106(6):1814-1819.
36. Mueller DW, Rehli M, Bosserhoff AK. MiRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma [published online ahead of print February 12, 2009]. J Invest Dermatol. 2009;129(7):1740-1751.
37. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005;436(7047):117-122.
38. Steingrimsson E, Copeland NG, Jenkins NA. Melanocytes and the microphthalmia transcription factor network. Annu Rev Genet. 2004:38365-38411.
39. Dhomen N, Marais R. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am. 2009;23(3):529-545.
40. Ozsolak F, Poling LL, Wang Z, et al. Chromatin structure analyses identify miRNA promoters. Genes Dev. 2008;22(22):3172-3183.
41. Roush S, Slack FJ. The let-7 family of microRNAs [published online ahead of print September 4, 2008]. Trends Cell Biol. 2008;18(10): 505-516.
42. Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res. 2008;18(5):549-557.
43. Müller DW, Bosserhoff AK. Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma [published online ahead of print August 4, 2008]. Oncogene. 2008;27(52):6698-6706.
44. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435(7043):828-833.
45. Landais S, Landry S, Legault P, Rassart E. Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia. Cancer Res. 2007;67(12):5699-5707.
46. Levati L, Alvino E, Pagani E, et al. Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155. Int J Oncol. 2009;35(2):393-400.
47. Alexeev V, Yoon K. Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol. 2006;126(5):1102-1110.
48. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma [published online ahead of print August 14, 2006]. J Clin Oncol. 2006;24(26):4340-4346.
49. Smalley KS, Contractor R, Nguyen TK, et al. Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res. 2008;68(14):5743-5752.
50. Huang S, Luca M, Gutman M, et al. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene. 1996;13(11):2339-2347.
51. Igoucheva O, Alexeev V. MicroRNA-dependent regulation of cKit in cutaneous melanoma [published online ahead of print January 4, 2009]. Biochem Biophys Res Commun. 2009;379(3):790-794.
52. Lopez-Bergami P, Fitchman B, Ronai Z. Understanding signaling cascades in melanoma [published online ahead of print December 15, 2007]. Photochem Photobiol. 2008;84(2):289-306.
53. Palmieri G, Capone M, Ascierto ML, et al. Main roads to melanoma. J Transl Med. 2009;7:86. Available at http://www.translational-medicine.com/content/7/1/86. Accessed 20 May 2010.
54. Smalley KS. Understanding melanoma signaling networks as the basis for molecular targeted therapy. J Invest Dermatol. 2010;130(1):28-37.
55. Zhang L, Deng T, Li X, et al. microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network [published online ahead of print January 6, 2010]. Carcinogenesis. 2010;31(4):559-566.
56. Garofalo M, Di Leva G, Romano G, et al. MiR-221 & 222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 2009;16(6):498-509.
57. Costoya JA, Hobbs RM, Pandolfi PP. Cyclin-dependent kinase antagonizes promyelocytic leukemia zinc-finger through phosphorylation [published online ahead of print February 4, 2008]. Oncogene. 2008;27(27):3789-3796.
58. Gottschalk AR, Basila D, Wong M, et al. p27Kip1 is required for PTEN-induced G1 growth arrest. Cancer Res. 2001;61(5):2105-2111.
59. Mamillapalli R, Gavrilova N, Mihaylova VT, et al. PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr Biol. 2001;11(4): 263-267.
60. Lee SG, Su ZZ, Emdad L, Sarkar D, Fisher PB. Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc [published online ahead of print November 6, 2006]. Proc Natl Acad Sci U S A. 2006; 103(46):17390-17395.
61. Thirkettle HJ, Mills IG, Whitaker HC, Neal DE. Nuclear LYRIC/AEG-1 interacts with PLZF and relieves PLZF-mediated repression [published online ahead of print August 3, 2009]. Oncogene. 2009;28(41):3663-3670.
62. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network [published online ahead of print June 6, 2007]. Nature. 2007;447(7148):1130-1134.
63. Lodygin D, Tarasov V, Epanchintsev A, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer [published online ahead of print August 1, 2008]. Cell Cycle. 2008;7(16):2591-2600.
64. Kitago M, Martinez SR, Nakamura T, Sim MS, Hoon DS. Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma [published online ahead of print March 31, 2009]. Clin Cancer Res. 2009;15(9):2988-2994.
65. Zhang Z, Sun H, Dai H, et al. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT [published online ahead of print September 29, 2009]. Cell Cycle. 2009;8(17): 2756-2768.
66. Xi Y, Nakajima G, Gavin E, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples [published online ahead of print August 13, 2007]. RNA. 2007;13(10):1668-1674.
67. Zhang X, Chen J, Radcliffe T, Lebrun DP, Tron VA, Feilotter H. An array-based analysis of microRNA expression comparing matched frozen and formalin-fixed paraffin-embedded human tissue samples [published online ahead of print October 2, 2008]. J Mol Diagn. 2008;10(6):513-519.
68. Cortez MA, Calin GA. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther. 2009;9(6):703-711.
69. Glud M, Klausen M, Gniadecki R, et al. MicroRNA expression in melanocytic nevi: the usefulness of formalin-fixed, paraffin-embedded material for miRNA microarray profiling [published online ahead of print November 13, 2009]. J Invest Dermatol. 2009;129(5):1219-1224.
70. Liu A, Tetzlaff MT, Vanbelle P, et al. MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues. Int J Clin Exp Pathol. 2009;2(6):519-527.
71. Ma Z, Lui WO, Fire A, Dadras SS. Profiling and discovery of novel miRNAs from formalin-fixed, paraffin-embedded melanoma and nodal specimens. J Mol Diagn. 2009;11(5):420-429.
72. Radhakrishnan A, Badhrinarayanan N, Biswas J, Krishnakumar S. Analysis of chromosomal aberration (1, 3, and 8) and association of microRNAs in uveal melanoma. Mol Vis. 2009:152146-152154.
73. Satzger I, Mattern A, Kuettler U, et al. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int J Cancer. 2010;126(11):2553-2562.
74. Sun Q, Cong R, Yan H, et al. Genistein inhibits growth of human uveal melanoma cells and affects microRNA-27a and target gene expression. Oncol Rep. 2009;22(3):563-567.
75. Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009;137(6):1005-1017.
76. Molnar V, Tamasi V, Bakos B, Wiener Z, Falus A. Changes in miRNA expression in solid tumors: an miRNA profiling in melanomas [published online ahead of print January 15, 2008]. Semin Cancer Biol. 2008;18(2):111-122.